Suppr超能文献

胶质母细胞瘤的立体定向放射外科手术 upfront 强化与术中放疗的剂量学比较

Dosimetric Comparison of Upfront Boosting With Stereotactic Radiosurgery Versus Intraoperative Radiotherapy for Glioblastoma.

作者信息

Sarria Gustavo R, Smalec Zuzanna, Muedder Thomas, Holz Jasmin A, Scafa Davide, Koch David, Garbe Stephan, Schneider Matthias, Hamed Motaz, Vatter Hartmut, Herrlinger Ulrich, Giordano Frank A, Schmeel Leonard Christopher

机构信息

Department of Radiation Oncology, University Hospital Bonn, Bonn, Germany.

Department of Neurosurgery, University Hospital Bonn, Bonn, Germany.

出版信息

Front Oncol. 2021 Oct 28;11:759873. doi: 10.3389/fonc.2021.759873. eCollection 2021.

Abstract

PURPOSE

To simulate and analyze the dosimetric differences of intraoperative radiotherapy (IORT) or pre-operative single-fraction stereotactic radiosurgery (SRS) in addition to post-operative external beam radiotherapy (EBRT) in Glioblastoma (GB).

METHODS

Imaging series of previously treated patients with adjuvant radiochemotherapy were analyzed. For SRS target definition, pre-operative MRIs were co-registered to planning CT scans and a pre-operative T1-weighted gross target volume (GTV) plus a 2-mm planning target volume (PTV) were created. For IORT, a modified (m)GTV was expanded from the pre-operative volume, in order to mimic a round cavity as during IORT. Dose prescription was 20 Gy, homogeneously planned for SRS and calculated at the surface for IORT, to cover 99% and 90% of the volumes, respectively. For tumors > 2cm in maximum diameter, a 15 Gy dose was prescribed. Plan assessment was performed after calculating the 2-Gy equivalent doses (EQD2) for both boost modalities and including them into the EBRT plan. Main points of interest encompass differences in target coverage, brain volume receiving 12 Gy or more (V), and doses to various organs-at-risk (OARs).

RESULTS

Seventeen pre-delivered treatment plans were included in the study. The mean GTV was 21.72 cm (SD ± 19.36) and mGTV 29.64 cm (SD ± 25.64). The mean EBRT and SRS PTV were 254.09 (SD ± 80.0) and 36.20 cm (SD ± 31.48), respectively. Eight SRS plans were calculated to 15 Gy according to larger tumor sizes, while all IORT plans to 20 Gy. The mean EBRT D was 97.13% (SD ± 3.48) the SRS D 99.91% (SD ± 0.35) and IORT D 83.59% (SD ± 3.55). Accounting for only-boost approaches, the brain V was 49.68 cm (SD ± 26.70) and 16.94 cm (SD ± 13.33) (p<0.001) for SRS and IORT, respectively. After adding EBRT results respectively to SRS and IORT doses, significant lower doses were found in the latter for mean D of chiasma (p=0.01), left optic nerve (p=0.023), right (p=0.008) and left retina (p<0.001). No significant differences were obtained for brainstem and cochleae.

CONCLUSION

Dose escalation for Glioblastoma using IORT results in lower OAR exposure as conventional SRS.

摘要

目的

模拟并分析胶质母细胞瘤(GB)患者在术后外照射放疗(EBRT)基础上,术中放疗(IORT)或术前单次分割立体定向放射外科治疗(SRS)的剂量学差异。

方法

分析既往接受辅助放化疗患者的影像序列。对于SRS靶区定义,将术前MRI与计划CT扫描进行配准,并创建术前T1加权增强靶区体积(GTV)加2mm的计划靶区体积(PTV)。对于IORT,从术前体积扩展出一个修正的(m)GTV,以模拟IORT期间的圆形腔隙。剂量处方为20Gy,SRS均匀计划,IORT在表面计算,分别覆盖99%和90%的体积。对于最大直径>2cm的肿瘤,处方剂量为15Gy。在计算两种增敏方式的2Gy等效剂量(EQD2)并将其纳入EBRT计划后进行计划评估。主要关注靶点覆盖、接受12Gy或更高剂量的脑体积(V)以及对各种危及器官(OARs)的剂量差异。

结果

本研究纳入了17个预先交付的治疗计划。平均GTV为21.72cm(标准差±19.36),mGTV为29.64cm(标准差±25.64)。平均EBRT和SRS的PTV分别为254.09(标准差±80.0)和36.20cm(标准差±31.48)。根据较大的肿瘤大小,8个SRS计划计算为15Gy,而所有IORT计划为20Gy。平均EBRT剂量为97.13%(标准差±3.48),SRS剂量为99.91%(标准差±0.35),IORT剂量为83.59%(标准差±3.55)。仅考虑增敏方法时,SRS和IORT的脑V分别为49.68cm(标准差±26.70)和16.94cm(标准差±13.33)(p<0.001)。将EBRT结果分别加入SRS和IORT剂量后,发现后者视交叉平均剂量(p=0.01)、左侧视神经(p=0.023)、右侧(p=0.008)和左侧视网膜(p<0.001)的剂量显著降低。脑干和耳蜗未获得显著差异。

结论

与传统SRS相比,胶质母细胞瘤使用IORT进行剂量递增可降低OARs的受照剂量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a800/8581360/6f81aec815f2/fonc-11-759873-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验